keyword
MENU ▼
Read by QxMD icon Read
search

Breast chemotherapy adjuvant and primary

keyword
https://www.readbyqxmd.com/read/29138761/a-metastasis-biomarker-metasite-breast%C3%A2-score-is-associated-with-distant-recurrence-in-hormone-receptor-positive-her2-negative-early-stage-breast-cancer
#1
Joseph A Sparano, Robert Gray, Maja H Oktay, David Entenberg, Thomas Rohan, Xiaonan Xue, Michael Donovan, Michael Peterson, Anthony Shuber, Douglas A Hamilton, Timothy D'Alfonso, Lori J Goldstein, Frank Gertler, Nancy E Davidson, John Condeelis, Joan Jones
Metastasis is the primary cause of death in early-stage breast cancer. We evaluated the association between a metastasis biomarker, which we call "Tumor Microenviroment of Metastasis" (TMEM), and risk of recurrence. TMEM are microanatomic structures where invasive tumor cells are in direct contact with endothelial cells and macrophages, and which serve as intravasation sites for tumor cells into the circulation. We evaluated primary tumors from 600 patients with Stage I-III breast cancer treated with adjuvant chemotherapy in trial E2197 (NCT00003519), plus endocrine therapy for hormone receptor (HR)+ disease...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29137653/prognostic-value-of-pam50-and-risk-of-recurrence-score-in-patients-with-early-stage-breast-cancer-with-long-term-follow-up
#2
Hege O Ohnstad, Elin Borgen, Ragnhild S Falk, Tonje G Lien, Marit Aaserud, My Anh T Sveli, Jon A Kyte, Vessela N Kristensen, Gry A Geitvik, Ellen Schlichting, Erik A Wist, Therese Sørlie, Hege G Russnes, Bjørn Naume
BACKGROUND: The aim of this study was to investigate the prognostic value of the PAM50 intrinsic subtypes and risk of recurrence (ROR) score in patients with early breast cancer and long-term follow-up. A special focus was placed on hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) pN0 patients not treated with chemotherapy. METHODS: Patients with early breast cancer (n = 653) enrolled in the observational Oslo1 study (1995-1998) were followed for distant recurrence and breast cancer death...
November 14, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29132326/association-between-gene-expression-profile-of-the-primary-tumor-and-chemotherapy-response-of-metastatic-breast-cancer
#3
Cemile Dilara Savci-Heijink, Hans Halfwerk, Jan Koster, Marc Joan Van de Vijver
BACKGROUND: To better predict the likelihood of response to chemotherapy, we have conducted a study comparing the gene expression patterns of primary tumours with their corresponding response to systemic chemotherapy in the metastatic setting. METHODS: mRNA expression profiles of breast carcinomas of patients that later developed distant metastases were analyzed using supervised and non-supervised classification techniques to identify predictors of response to chemotherapy...
November 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29128896/discordance-between-oncotype-dx-recurrence-score-and-rspc-for-predicting-residual-risk-of-recurrence-in-er-positive-breast-cancer
#4
Andrew Dodson, David Okonji, Laura Assersohn, Anne Rigg, Amna Sheri, Nick Turner, Ian Smith, Marina Parton, Mitch Dowsett
PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy. METHODS: Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear...
November 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29100362/the-prognostic-significance-of-combined-androgen-receptor-e-cadherin-ki67-and-ck5-6-expression-in-patients-with-triple-negative-breast-cancer
#5
Barbara Adamo, Giuseppina Rosaria Rita Ricciardi, Antonio Ieni, Tindara Franchina, Carmine Fazzari, Maria Vita Sanò, Giuseppe Angelico, Caruso Michele, Giovanni Tuccari, Vincenzo Adamo
Background: Triple Negative Breast Cancer (TNBC) represents a heterogeneous group of tumors with poor prognosis owing to aggressive tumor biology and lack of targeted therapies. No clear prognostic biomarkers have been identified to date for this subgroup. Materials and Methods: In this retrospective study we evaluated the prognostic role of 4 different molecular determinants, including androgen receptor (AR), E-cadherin (CDH1), Ki67 index, and basal cytokeratins (CKs) 5/6, in a cohort of 99 patients with TNBC...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29096156/recurrence-dynamics-of-breast-cancer-according-to-baseline-body-mass-index
#6
Elia Biganzoli, Christine Desmedt, Marco Fornili, Evandro de Azambuja, Nathalie Cornez, Fernand Ries, Marie-Thérèse Closon-Dejardin, Joseph Kerger, Christian Focan, Angelo Di Leo, Jean-Marie Nogaret, Christos Sotiriou, Martine Piccart, Romano Demicheli
BACKGROUND: In cancer follow-up, in addition to the evaluation of survival probabilities, there is a fundamental need of assessing recurrence dynamics for optimal disease management. Although the time-dependent effect of the oestrogen receptor (ER) status of the tumour has already been described, so far no factor has proven to disentangle the multi-peak behaviour observed for breast cancer recurrences. Here, we aimed at investigating whether adiposity at diagnosis, reflected by increased patient's body mass index (BMI), could be associated with breast cancer recurrence patterns over time after primary cancer therapy...
October 30, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29091014/development-of-a-novel-prognostic-score-for-breast-cancer-patients-using-mrna-expression-of-chac1
#7
Beate Jahn, Marjan Arvandi, Ursula Rochau, Heidi Fiegl, Georg Goebel, Christian Marth, Uwe Siebert
AIM: To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions. PATIENTS & METHODS: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression. RESULTS: The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy...
October 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29069370/ten-year-results-of-intense-dose-dense-chemotherapy-show-superior-survival-compared-to-a-conventional-schedule-in-high-risk-primary-breast-cancer-final-results-of-ago-phase-iii-iddepc-trial
#8
V Möbus, C Jackisch, H J Lueck, A du Bois, C Thomssen, W Kuhn, U Nitz, A Schneeweiss, J Huober, N Harbeck, G von Minckwitz, I B Runnebaum, A Hinke, G E Konecny, M Untch, C Kurbacher, S Kahlert, N Hauser, F Marmé, L Kiesel, D Wallwiener, B Rautenberg, R Hofmann, J Barinoff, E Stickeler, H Eidtmann, V Müller, G Emons, P Mallmann, R Hackenberg, C Hielscher, G Räber, H Sommer, P Schmidt-Rhode, B Jahns, A von der Assen, S Dietterle, M Kaufmann, C Strunk, R Goebel, S Paepke, A Paulenz, A Junker-Stein, U Rhein, K Bremer, W Bauer, P Hohlweg-Majert, D Kramer, H-G Meerpohl, K Diedrich, P Dall, H Kölbl, B Brückner, R Gros, H Stehle, K Lobodasch, T Dinkelacker, E Klöpper, C Karg, M Stibora, W Weise, F Melchert, S Mohrmann, C Klatt, M Schmidt, M Glados, H Mickan, A Pollmanns, T Beck, W Schröder, H Klingemann, G Köhler, W Freier, S-T Graßhoff, U Söling, E Keil, C Höß, U Kullmer, A Niesel, H Bodenstein, G Bartzke, C M Schlotter, W Wiest, W Ernst, O Brudler, B Heinrich, J Hackmann, W Niedner, G Hoffmann, W Knapp, G Dresemann, C Karl, F-J Klemm, G C Schliesser, M Butterwegge, H Meden, M Kirschbaum, T Schwenzer, H-J Voigt, U Weiß, G Önder, W Langer, M Glaubitz, M Beha, A Coumbos, Y Ko, J-U Deuker, O Prümmer, U Wagner, A Kohlstedt, P Schreiber, V Jovanovic, K Drzewiecki, H Guba, H Seipt, M Stauch, C Maintz, B Morenz
Background: Primary breast cancer patients with extensive axillary lymph-node involvement have a limited prognosis. The AGO (Arbeitsgemeinschaft fuer Gynaekologische Onkologie) trial compared intense dose-dense adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk breast cancer patients. Here we report the final, 10-year follow-up analysis. Patients and methods: Enrolment took place between December 1998 until April 2003. 1284 patients with four or more involved axillary lymph nodes were randomly assigned to receive three courses each of intense dose-dense sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC&cenveo_unknown_entity_wingdings_F0E0;P) q3w...
October 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29054689/breast-cancer-survivorship-care-variations-between-adjuvant-chemotherapy-regimens
#9
Alexis D Leal, Holly Van Houten, Lindsey Sangaralingham, Rachel A Freedman, Ahmedin Jemal, Heather B Neuman, Tufia C Haddad, Robert W Mutter, Theresa H M Keegan, Sarah S Mougalian, Charles L Loprinzi, Cary P Gross, Nilay Shah, Kathryn J Ruddy
BACKGROUND: Treatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use. MATERIALS AND METHODS: We analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014...
September 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29052527/negative-genic-switch-of-her-2-in-the-primary-tumor-instead-of-the-synchronous-metastatic-nodal-lesions-after-neoadjuvant-chemotherapy-in-a-patient-with-primary-her2-positive-breast-cancer
#10
Hao-Ran Chen, Yu-Tuan Wu, Qiu-Bo Yu, Ya-Ying Yang, Yu-Xian Wei, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
BACKGROUND: A few retrospective studies have indicated that neoadjuvant chemotherapy (NAC) in breast cancer may change biomarker profiles of the primary tumor. Little is known about the status of HER-2 gene of the synchronous nodal metastases when that of the residual tumor undergoes negative conversion in a neoadjuvant setting. CASE PRESENTATION: We describe a female patient with left breast cancer (T2N2M0) who underwent negative conversion of HER-2 in the primary tumor instead of the synchronous nodal lesions after NAC...
October 19, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29048972/new-persistent-opioid-use-among-patients-with-cancer-after-curative-intent-surgery
#11
Jay Soong-Jin Lee, Hsou Mei Hu, Anthony L Edelman, Chad M Brummett, Michael J Englesbe, Jennifer F Waljee, Jeffrey B Smerage, Jennifer J Griggs, Hari Nathan, Jacqueline S Jeruss, Lesly A Dossett
Purpose The current epidemic of prescription opioid misuse has increased scrutiny of postoperative opioid prescribing. Some 6% to 8% of opioid-naïve patients undergoing noncancer procedures develop new persistent opioid use; however, it is unknown if a similar risk applies to patients with cancer. We sought to define the risk of new persistent opioid use after curative-intent surgery, identify risk factors, and describe changes in daily opioid dose over time after surgery. Methods Using a national data set of insurance claims, we identified patients with cancer undergoing curative-intent surgery from 2010 to 2014...
October 19, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29047418/primary-small-cell-carcinoma-of-the-breast-a-case-report
#12
Iman Abou Dalle, Jaber Abbas, Fouad Boulos, Ziad Salem, Hazem I Assi
BACKGROUND: Neuroendocrine breast cancer is a rare entity that was defined in 2003 by the World Health Organization as a separate breast cancer subtype. The diagnosis of neuroendocrine breast cancer requires the presence of neuroendocrine features in at least 50% of malignant cells, the exclusion of non-mammary primary tumors, as well as the presence of an in situ component in breast histology. The treatment and prognosis of neuroendocrine breast cancer are still not well established...
October 19, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29046702/in-vivo-validation-of-metastasis-regulating-microrna-766-in-human-triple-negative-breast-cancer-cells
#13
Keunhee Oh, Dong-Sup Lee
Breast cancer is the second most common cancer and the most frequent cancer in women worldwide. Recent improvements in early detection and effective adjuvant chemotherapies have improved the survival of breast cancer patients. Even with initial disease remission, one-third of all breast cancer patients will relapse with distant metastasis. Breast cancer metastasis is largely an incurable disease and the main cause of death among breast cancer patients. Cancer metastasis is comprised of complex processes that are usually not controllable by intervention of a single molecular target...
September 2017: Laboratory Animal Research
https://www.readbyqxmd.com/read/29045452/prospective-multicenter-french-study-evaluating-the-clinical-impact-of-the-breast-cancer-intrinsic-subtype-prosigna%C3%A2-test-in-the-management-of-early-stage-breast-cancers
#14
MULTICENTER STUDY
Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, Jean-Marc Guinebretière, John Hornberger, Frédérique Penault-Llorca, Roman Rouzier
PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results...
2017: PloS One
https://www.readbyqxmd.com/read/29037213/personalized-treatment-of-women-with-early-breast-cancer-a-risk-group-specific-cost-effectiveness-analysis-of-adjuvant-chemotherapy-accounting-for-companion-prognostic-tests-oncotypedx-and-adjuvant-online
#15
Beate Jahn, Ursula Rochau, Christina Kurzthaler, Michael Hubalek, Rebecca Miksad, Gaby Sroczynski, Mike Paulden, Marvin Bundo, David Stenehjem, Diana Brixner, Murray Krahn, Uwe Siebert
BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX, ODX) is a promising prognostic score for risk stratification that can be applied in conjunction with Adjuvant!Online (AO) to guide personalized chemotherapy decisions for early BC patients...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28982914/surgical-resection-and-outcome-of-synchronous-and-metachronous-primary-lung-cancer-in-breast-cancer-patients
#16
Fumihiro Shoji, Nami Yamashita, Yuka Inoue, Yuka Kozuma, Gouji Toyokawa, Fumihiko Hirai, Kensaku Ito, Tetsuzo Tagawa, Tatsuro Okamoto, Yoshihiko Maehara
BACKGROUND/AIM: Women with breast cancer are at increased risk of subsequent primary malignancies, specifically lung cancer. The aim of this study was to report the frequency of lung cancer in patients with breast cancer, and patients' characteristics and surgical outcomes. PATIENTS AND METHODS: We investigated 1,066 consecutive female patients undergoing surgical resection for breast cancer and 666 undergoing surgical resection for lung cancer. RESULTS: Lung cancer with breast cancer was observed in 14 patients (1...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982874/impact-of-calgb-9343-trial-and-sociodemographic-variation-on-patterns-of-adjuvant-radiation-therapy-practice-for-elderly-women-%C3%A2-70-years-with-stage-i-estrogen-receptor-positive-breast-cancer-analysis-of-the-national-cancer-data-base
#17
Quyen D Chu, Meijiao Zhou, Kaelen L Medeiros, Prakash Peddi, Xiao Cheng Wu
BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28970847/meeting-highlights-the-second-consensus-conference-for-breast-cancer-treatment-in-korea
#18
Seeyoun Lee, In Hae Park, Seho Park, Joohyuk Sohn, Joon Jeong, Sung Gwe Ahn, Ik Jae Lee, Hae Kyung Lee, Seung Ah Lee, Won Park, Kyung-Hun Lee, Sung-Won Kim, Sang-Ah Han, Kyung Hae Jung, Byung Ho Son
The Korean clinical practice guideline recently developed by the Korean Breast Cancer Society to address the national clinical situation is currently under revision ahead of a seventh recommendation. A second consensus conference was held to further develop this guideline by soliciting opinions regarding important issues related to surgery, radiotherapy, and medical oncology. Several issues were discussed, and the discussion progressed to pros and cons in the context of cases in various clinical situations...
September 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28961844/revisiting-the-definition-of-estrogen-receptor-positivity-in-her2-negative-primary-breast-cancer
#19
T Fujii, T Kogawa, W Dong, A A Sahin, S Moulder, J K Litton, D Tripathy, T Iwamoto, K K Hunt, L Pusztai, B Lim, Y Shen, N T Ueno
Background: Although 1% has been used as cut-off for estrogen receptor (ER) positivity, several studies have reported that tumors with ER < 1% have characteristics similar to those with 1% ≤ ER < 10%. We hypothesized that in patients with human epidermal growth factor 2 (HER2)-negative breast cancer, a cut-off of 10% is more useful than one of 1% in discriminating for both a better pathological complete response (pCR) rate to neoadjuvant chemotherapy and a better long-term outcome with adjuvant hormonal therapy...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28959168/electrochemotherapy-supplementary-treatment-for-loco-regional-metastasized-breast-carcinoma-administered-to-concomitant-systemic-therapy
#20
Eva-Maria Grischke, Carmen Röhm, Eva Stauß, Florin-Andrei Taran, Sara Y Brucker, Diethelm Wallwiener
BACKGROUND: Electrochemotherapy (ECT) is an established procedure for treating breast cancer loco-regional recurrences following surgical intervention and/or radiotherapy. Limited information is available on ECT application as a concomitant procedure to systemic therapy in recurrent breast cancer. The primary objective of this study was to determine if the application of ECT in close temporal relation to systemic chemotherapy could lead to increased local and/or systemic side effects...
September 2017: Radiology and Oncology
keyword
keyword
43929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"